# Switched Memory B-cells as a Marker for Humoral Immune System Recovery in Patients With Secondary Antibody Deficiency Due to Hematological Malignancies

> **NCT05612607** · PHASE4 · UNKNOWN · sponsor: **Ottawa Hospital Research Institute** · enrollment: 100 (estimated)

## Conditions studied

- Secondary Antibody Deficiency

## Interventions

- **DRUG:** Immunoglobulin replacement therapy (IGRT)

## Key facts

- **NCT ID:** NCT05612607
- **Lead sponsor:** Ottawa Hospital Research Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-11-10
- **Primary completion:** 2023-10-10
- **Final completion:** 2025-12-31
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2022-11-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05612607

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05612607, "Switched Memory B-cells as a Marker for Humoral Immune System Recovery in Patients With Secondary Antibody Deficiency Due to Hematological Malignancies". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT05612607. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*